Jw Pharmac

KOSE:A001060

South Korea / Healthcare / Pharmaceuticals

Overview

News

5Y Historical Financials

Stock Price

21,050.00 KRW


Key Metrics	Latest
Total Revenue	719.4 B
Adjusted EBITDA	101.8 B
EBITDA Margin	14.2%
Net Profit Margin	9.0%
Total Assets	604.6 B
Total Debt	91.726 B

5Y Historical Financial Statements

Summary Financials


Summary Financials

	Fiscal Year Ending					Latest	Year-to-date Ending
(in millions)	Dec-20	Dec-21	Dec-22	Dec-23	Dec-24	12 Months	Dec-23	Dec-24

Revenue	547,335.71	606,584.94	684,351.10	748,526.71	719,375.76	719,375.76	748,526.71	719,375.76
% Growth		0.11	0.13	0.09	(0.04)			(0.04)

Adjusted EBITDA	19,365.18	46,959.60	77,326.75	119,205.62	101,833.74	101,833.74	119,205.62	101,833.74
% Margin	0.04	0.08	0.11	0.16	0.14	0.14	0.16	0.14

Adjusted EBIT	(1,322.98)	30,847.85	60,490.43	96,631.03	82,732.51	82,732.51	96,631.03	82,732.51
% Margin	(0.00)	0.05	0.09	0.13	0.12	0.12	0.13	0.12

Adjusted Net Income	(15,266.41)	(187.63)	40,009.89	37,141.29	65,017.99	65,017.99	37,141.29	65,017.99
% Margin	(0.03)	(0.00)	0.06	0.05	0.09	0.09	0.05	0.09

Adjusted Basic EPS	(657.46)	(8.08)	1,722.68	1,560.34	2,787.53	2,787.53	1,560.34	2,787.53

Supporting Calculations

Income Statement

Balance Sheet

Statement of Cashflows


Income Statement
						Original
KRW	Fiscal Year Ending					Latest	Year-to-date Ending
(in millions)	Dec-20	Dec-21	Dec-22	Dec-23	Dec-24	Dec-24	Dec-23	Dec-24
	FY - 4	FY - 3	FY - 2	FY - 1	FY	LTM	YTD-1	YTD

Revenue	547,336	606,585	684,351	748,527	719,376	719,376	748,527	719,376
% Growth	NA	10.8%	12.8%	9.4%	-3.9%			-3.9%

Cost of Revenue	(369,810)	(372,209)	(396,397)	(412,984)	(395,878)	(395,878)	(412,984)	(395,878)
Gross Profit	177,526	234,376	287,955	335,542	323,498	323,498	335,542	323,498
% Revenue	32.4%	38.6%	42.1%	44.8%	45.0%	45.0%	44.8%	45.0%

Research and Development	(22,943)	(19,884)	(33,736)	(33,671)	(36,237)	(36,237)	(33,671)	(36,237)
Selling and Marketing	(25,890)	(29,573)	(35,516)	(35,864)	(37,110)	(37,110)	(35,864)	(37,110)
General and Admin	(130,015)	(154,072)	(158,212)	(169,376)	(167,418)	(167,418)	(169,376)	(167,418)
Other Inc / (Exp)	(4,928)	(4,960)	(11,556)	(35,555)	4,758	4,758	(35,555)	4,758
Total Operating Exp	(183,776)	(208,488)	(239,020)	(274,467)	(236,007)	(236,007)	(274,467)	(236,007)

Operating Income	(6,251)	25,888	48,934	61,076	87,491	87,491	61,076	87,491
% Revenue	-1.1%	4.3%	7.2%	8.2%	12.2%	12.2%	8.2%	12.2%

Interest Expense	(6,954)	(5,356)	(3,572)	(6,239)	(5,071)	(5,071)	(6,239)	(5,071)
Pre-tax Income	(13,205)	20,533	45,362	54,836	82,420	82,420	54,836	82,420
Earnings of Discontinued Ops.	0	0	0	0	0	0	0	0
Provision for Taxes	(2,070)	(21,974)	(15,509)	(16,406)	(17,379)	(17,379)	(16,406)	(17,379)
Net Income to Company	(15,275)	(1,441)	29,853	38,430	65,040	65,040	38,430	65,040
% Margin	-2.8%	-0.2%	4.4%	5.1%	9.0%	9.0%	5.1%	9.0%

Minority Interest in Earnings	34	474	2,039	(1,424)	0	0	(1,424)	0
Net Income to Stockholders	(15,241)	(968)	31,892	37,006	65,040	65,040	37,006	65,040

Preferred Dividends	0	0	0	0	0	0	0	0
Other Adj.	0	0	0	0	0	0	0	0

Net Income to Common	(15,241)	(968)	31,892	37,006	65,040	65,040	37,006	65,040
% Margin	-2.8%	-0.2%	4.7%	4.9%	9.0%	9.0%	4.9%	9.0%

As Reported
Basic EPS (Continuing Ops)	(656.37)	(41.70)	1,373.14	1,554.67	2,788.47	2,788.47	1,554.67	2,788.47
Diluted EPS (Continuing Ops)	(656.37)	(41.70)	1,373.14	1,554.67	2,788.47	2,788.47	1,554.67	2,788.47

WA Basic Shares Out.	23.22	23.21	23.23	23.80	23.32	23.32	23.80	23.32
WA Diluted Shares Out.	23.22	23.21	23.23	23.80	23.32	23.32	23.80	23.32

EBITDA, EBIT Reconciliation
EBT, Incl. Unusual Items	(13,205)	20,533	45,362	54,836	82,420	82,420	54,836	82,420
Addback: Net Interest Expense	6,954	5,356	3,572	6,239	5,071	5,071	6,239	5,071
Addback: Other Non Operating Expenses, Total	4,916	3,265	(2,170)	37,297	(4,728)	(4,728)	37,297	(4,728)
Addback: Depreciation & Amortization	20,688	16,112	16,836	22,575	19,101	19,101	22,575	19,101
Addback: Restructuring Charges	0	0	0	0	0	0	0	0
Addback: Merger / Acquisition Expenses	0	0	0	0	0	0	0	0
Addback: Goodwill Impairment	0	0	0	0	0	0	0	0
Addback: Gain (Loss) On Sale Of Invest.	0	647	8,908	(2,830)	(791)	(791)	(2,830)	(791)
Addback: Gain (Loss) On Sale Of Assets	12	1,048	(3)	1,088	(465)	(465)	1,088	(465)
Addback: Asset Writedown	0	0	4,821	0	1,476	1,476	0	1,476
Addback: In Process R&D Expenses	0	0	0	0	0	0	0	0
Addback: Insurance Settlements	0	0	0	0	0	0	0	0
Addback: Legal Settlements	0	0	0	0	0	0	0	0
Addback: Other Unusual Items	0	0	0	0	(250)	(250)	0	(250)
Adjusted EBITDA	19,365	46,960	77,327	119,206	101,834	101,834	119,206	101,834
% Margin	3.5%	7.7%	11.3%	15.9%	14.2%	14.2%	15.9%	14.2%

Adjusted EBIT	(1,323)	30,848	60,490	96,631	82,733	82,733	96,631	82,733
% Margin	-0.2%	5.1%	8.8%	12.9%	11.5%	11.5%	12.9%	11.5%

Adjusted Net Income Reconciliation
Net Income to Company	(15,275)	(1,441)	29,853	38,430	65,040	65,040	38,430	65,040
Addback: Unusual Items	12	1,694	13,726	(1,742)	(30)	(30)	(1,742)	(30)
Less: Tax Benefit of Unusual Items (26%)	(3)	(441)	(3,569)	453	8	8	453	8
Adjusted Net Income	(15,266)	(188)	40,010	37,141	65,018	65,018	37,141	65,018
% Margin	-2.8%	0.0%	5.8%	5.0%	9.0%	9.0%	5.0%	9.0%

Loading Error

Jw Pharmac

KOSE:A001060

South Korea / Healthcare / Pharmaceuticals

5Y Historical Financials